Pharmaceutical company optimistic as products prepare for market

Pharmaceutical company N4 Pharma is looking forward “with great optimism” with it now having “a clear path” to get its products to market.

The Derby-based company specialises in cancer treatments and vaccines through its Nuvec delivery system.

Chief executive Nigel Theobald said: “2023 was a year of good progress for the company with material advancements in the capabilities of Nuvec both in its ability to dual load and in its potential for oral delivery.

“We achieved our objective of expanding our portfolio through our interest in Nanogenics which brings us a clear path for taking a product to market and the potential for orphan drug designation.”

The acquisition of a stake in Nanogenics Limited broadens N4 Pharma’s capabilities with Liptide, a complementary delivery system.

Established in 2014, the company has pursued testing to improve existing products and develop new ones.

N4 Pharma secured patents in various countries, including Europe, Australia, Japan, China, the U.S. and India.

Theobald said: “Our IP position has strengthened and we believe we are closer than ever before to agreeing on a collaboration which would see Nuvec being applied to other technologies with a view to co-marketing the resultant technology to big pharma and I look forward to making further announcements on this shortly.

N4 Pharma has also disclosed its financial results for 2023, showing a loss of £1.2m, compared to £1m in 2022. It had £1.0m in cash at the year-end.

“We continue to manage our cash position tightly and look forward to the rest of 2024 with great optimism,” added Theobald.